—Õ°–òŠw

 

’˜@‘

 

1)         ¼ŒûHŽi: ˆã—ÖòŠw. ‘æ5”Å, –x@—¹•½@ŠÄC, Š£@Œ«ˆê‚ç@•ÒW, œAì‘“X (2009).

 

2)         ¼ŒûHŽi: ŽÀ–±ŽÀKŽ–‘OŠwK‚Ì‚½‚ß‚Ì’²ÜŠw, ŽÄ賟‚ç@ŠÄC, Œú“cKˆê˜Y‚ç@•ÒW, œAì‘“X (2009).

 

3)         ¼ŒûHŽi: ƒVƒiƒŠƒIÇ—á‰ðÍ -ˆã—Â̌»ê‚Å¡c-, ‚ŽR@–¾@•ÒW, œAì‘“X (2009).

 

˜_@•¶

 

1)         Marie Nagai, Takahiro Fukamachi, Masayuki Tsujimoto, Kenichiro Ogura, Akira Hiratsuka, Hisakazu Ohtani, Satoko Hori, Yasufumi Sawada: Inhibitory effects of herbal extracts on the activity of human sulfotransferase isoform sulfotransferase 1A3 (SULT1A3). Biol. Pharm. Bull., 32, 105-109 (2009). 

 

2)         ú㌴»Žq, ŽRXŒ³”Ž, ’†‘º@”C, ¼ŒûHŽi, ‰œ–ì’BÆ, ’ƒ‰®Œ´Ø•äŽq, ŽO–ض–ç, “c‘ºF—Y, •½ˆä‚Ý‚Ç‚è, •Ð‰ª˜aŽO˜Y, ‰h“c•q”V: H“¹‚ª‚ñ‰»Šw•úŽËü—Ö@‚É‚¨‚¯‚é5-ƒtƒ‹ƒIƒƒEƒ‰ƒVƒ‹ŒŒŸ÷’†”Z“x‚Æ•›ì—p‚Æ‚Ì‘ŠŠÖ. TDMŒ¤‹†, 26, 7-13 (2009).

 

3)         Sayo Horibe, Kohji Takara, Tetsuya Minegaki, Noriaki Ohnishi, Teruyoshi Yokoyama: Distribution of ABCG2 (BCRP) and ABCC2 (MRP2) mRNAs in rat small intestine and liver. EXCLI Journal, 8, 12-19 (2009).

 

4)         •õŠ_“N–ç, ¬—Ñ@–r, V@NŒ›, –k“c“¿º, X“c‘Žq, ‹g‰ª–r“W, ’Ò@—²Žu, “n@‰ëŽ, •“¡r•F, £”ö@“O: •ó’ËŽs—§•a‰@‚É‚¨‚¯‚é‰@“à»Üƒuƒ[Ž‰t‚Ì—Õ°Žg—pŒoŒ±. Ž¨•@‚Æ—Õ°, 55, 26-30 (2009).

 

5)         Jahye Kim, Hisakazu Ohtani, Masayuki Tsujimoto, Yasufumi Sawada: Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal anti-inflammatory agents. Drug Metab. Pharmacokinet., 24, 167-174 (2009).

 

6)         Fumiaki Kitazawa, Toshio Abe, Kumi Ueda, Satoshi Murakami, Kohshi Nishiguchi, Kohji Takara, Teruyoshi Yokoyama, Hikofumi Sugii: Relation of age with myelosuppression induced by the CHOP regimen in patients with Non-Hodgkinfs Lymphoma. Cancer Therapy, 7, 133-140 (2009).

 

7)         Masayuki Tsujimoto, Maya Horie, Hiroko Honda, Kohji Takara, Kohshi Nishiguchi: The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. Biol. Pharm. Bull., 32, 671-676 (2009).

 

8)         Tsutomu Nakamura, Noboru Okamura, Mariko Yagi, Hideki Omatsu, Motohiro Yamamori, Akiko Kuwahara, Kohshi Nishiguchi, Masanori Horinouchi, Katsuhiko Okumura, Toshiyuki Sakaeda: Effects of ABCB1 3435C>T genotype on serum levels of cortisol and aldosterone in women with normal menstrual cycles. Genet. Mol. Res., 8, 397-403 (2009).

 

9)         Kyohei Shintaku, Satoko Hori, Masayuki Tsujimoto, Hideaki Nagata, Shoji Satoh, Kiyomi Tsukimori, Hitoo Nakano, Tomoyuki Fujii, Yuji Taketani, Hisakazu Ohtani, Yasufumi Sawada: Transplacental pharmacokinetics of diclofenac in perfused human placenta. Drug Metab. Dispos., 37, 962-968 (2009).

 

10)     Kohji Takara, Noriaki Kitada, Eri Yoshikawa, Kazuhiro Yamamoto, Sayo Horibe, Toshiyuki Sakaeda, Kohshi Nishiguchi, Noriaki Ohnishi, Teruyoshi Yokoyama: Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett., 278, 88-96 (2009).

 

11)     Akiko Kuwahara, Motohiro Yamamori, Kohshi Nishiguchi, Tatsuya Okuno, Naoko Chayahara, Ikuya Miki, Takao Tamura, Tsubasa Inokuma, Yoshiji Takemoto, Tsutomu Nakamura, Kazusaburo Kataoka, Toshiyuki Sakaeda: Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int. J. Med. Sci., 6, 305-311 (2009).

 

12)     –k“c“¿º, ¼–ì‰ës, ˆÀ“c@, X“c‘Žq, “¡ˆäç‰ê, •õŠ_“N–ç, ‹ß“¡–œ—F”ü, ˆ¢“ìߎq, ‚—ÇPŽj, “n@‰ëŽ: ˆê”Ê•a‰@‚É‚¨‚¯‚é“û‚ª‚ñ‰»Šw—Ö@‚Ì‹Ï‚Ä‚ñ‰»‚ð‚ß‚´‚µ‚Ä (‘æ2•ñj-FEC‚¨‚æ‚ÑTC—Ö@‚É‚¨‚¯‚éˆÀ‘S«‚ÌŒŸ“¢-. Šà‚Ɖ»Šw—Ö@, 36, 1671-1675 (2009).

 

 

 

‘@à

 

1)           Toshiyuki Sakaeda, Motohiro Yamamori, Akiko Kuwahara, Kohshi Nishiguchi: Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv. Drug Deliv. Rev., 61, 388-401(2009).

 

Šw‰ï”­•\“™

 

@@@Šw‰ï”­•\

 

1)       “°‰º^—œ, ¬’r”ü, –å˜e—SŽq, ‰Ô–[‰Á“ÞŒb, ŒÜ•S‘ •Žm, ˜a“c@“Ö, ŠpŽRD, ê –{”Ž—Y, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è: ˆÀ‘S‚ÈŠO—ˆ‰»Šw—Ö@‚É‚¨‚¯‚é–òÜŽt‚Ì–ðŠ„‚É‚Â‚¢‚Ä, ‘æ30‰ñ“ú–{•a‰@–òÜŽt‰ï@‹ß‹EŠwp‘å‰ï (‘åã), 2009. 1. 24-25.

 

2)       a’J“Þ•ä, …“c’¼”ü, A“c‹MŽj, ‘å¼G–¾, ŽR‰º˜a•F, ŠpŽRD, ê –{”Ž—Y, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è, rì‘nˆê, Šâ“cŒ’‘¾˜Y: Žèp•”ƒTƒeƒ‰ƒCƒg–ò‹Ç‚̉^—p‚ÆŽèp’†‚ÌR‹Û–òŽg—p•û–@‚Ì“K³‰», ‘æ30‰ñ“ú–{•a‰@–òÜŽt‰ï@‹ß‹EŠwp‘å‰ï (‘åã), 2009. 1. 24-25.

 

3)       ¬–ì—R‰Á—¢, A“c‹MŽj, “c’†Œ’‘¾, ŽRXŒ³”Ž, Šp–{Š²•v, ŠpŽRD, ê –{”Ž—Y, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è: ƒ^ƒNƒƒŠƒ€ƒXŒŒ’†”Z“x‘ª’è‚É‚¨‚¯‚éACMIA–@‚ÆMEIA–@‚Ì”äŠr, ‘æ30‰ñ“ú–{•a‰@–òÜŽt‰ï@‹ß‹EŠwp‘å‰ï (‘åã), 2009. 1. 24-25.

 

4)       A“c‹MŽj, Šp–{Š²•v, ŽRXŒ³”Ž, ŠpŽRD, ê –{”Ž—Y, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è: tˆÚAŠ³ŽÒ‚É‚¨‚¯‚éƒ^ƒNƒƒŠƒ€ƒX‚ƃvƒƒgƒ“ƒ|ƒ“ƒv‘jŠQÜ‚Ì–ò•¨‘ŠŒÝì—p, ‘æ30‰ñ“ú–{•a‰@–òÜŽt‰ï@‹ß‹EŠwp‘å‰ï (‘åã), 2009. 1. 24-25.

 

5)       ŠÛŽR“Þ•ä, ŠpŽRD, Šp–{Š²•v, ê –{”Ž—Y, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è: ƒwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒ¸­Ç(HIT)‚ÉŠÖ‚·‚éˆã—Ã]Ž–ŽÒ‚Ì”FŽ¯“x’²¸, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.

 

6)       ã“cC•½, 웽´, ‘Œ©‹±Žq, ‘º“c¬”Í, –؉ºŒ’Ži, ‹g“c–¾O, Šp–{Š²•v, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è: ƒƒ‹ƒtƒ@ƒŠƒ“ŽŠ“K“Š—^—ÊŒˆ’è‚É‚¨‚¯‚éASP-PCR–@‚ð—p‚¢‚½ˆâ“`ŽqŒ^”»’è‚Ì—L—p«, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.

 

 

7)       ŽR–{˜aG, Œ´@Œ«‘¾, ‰i“c³’j, ‚—ÇPŽj, ¼ŒûHŽi, •½ˆä‚Ý‚Ç‚è, ‰¡–ì_ˆê: ƒ‰ƒpƒ}ƒCƒVƒ“•W“Iƒ^ƒ“ƒpƒNŽ¿(mTOR)ƒVƒOƒiƒ‹“`’BŒn‚̉h—{Š´’mƒVƒXƒeƒ€‚Æ‚µ‚Ä‚Ì–ðŠ„‚Æ‚»‚Ì•ªŽqƒƒJƒjƒYƒ€, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.

 

8)       –{“chŽq, ’Ò–{‰ë”V, ¬ì”ü•äŽq, ‘“c‰À‘ãŽq, ‰ª–{ŠG—¢, ¬–ì¹K, ‚—ÇPŽj, ¼ŒûHŽi: –ò•¨‚ÌÁ‰»ŠÇ–Œ“§‰ß«‚É‹y‚Ú‚·ŠeŽíˆù—¿Ž‘±”˜˜I‚̉e‹¿, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.

 

9)       ’Ò–{‰ë”V: “§ÍŠ³ŽÒ‚É‚¨‚¯‚étŠOƒNƒŠƒAƒ‰ƒ“ƒX‚Ì•Ï“®GƒVƒ“ƒ|ƒWƒEƒ€13u“§Í‚É‚¨‚¯‚é–ò•¨“Š—^‚Ì–â‘è“_vC‘æ54‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ïE‘‰ï (‰¡•l)C2009. 6. 5-7.

 

10)    ‰¡“clŽm, ’Ò–{‰ë”V, ”µ›½‘å‰î, ´…–ƒ—Œb, ŽR–{_Žj, ™–{ŽÑ—œ, ’·—F–ƒ‹KŽq, •õŠ_“N–ç, ‚—ÇPŽj, ¼ŒûHŽi: –«t•s‘Sƒ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‚Ì‘gD“ÁˆÙ“I‚È”­Œ»•Ï“®, ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2009^‘æ17‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (‹ž“s) C2009. 7. 11-12.

 

11)    –{“chŽq, ’Ò–{‰ë”V, ‘“c‰À‘ãŽq,  ¬ì”ü•äŽq, ‰ª–{ŠG—¢, ‚—ÇPŽj, ¼ŒûHŽi: Á‰»ŠÇ‚É‚¨‚¯‚é–ò•¨ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‚É‹y‚Ú‚·ƒtƒ‰ƒ{ƒmƒCƒhŠÜ—Lˆù—¿‚ÌŽ‘±”˜˜I‚̉e‹¿, ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2009^‘æ17‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (‹ž“s), 2009. 7. 11-12.

 

12)    ‰¡“clŽm, ’Ò–{‰ë”V, ™–{ŽÑ—œ, ’·—F–ƒ‹KŽq, •õŠ_“N–ç, ¼ŒûHŽi: t•s‘SisˆöŽq‚Å‚ ‚éƒCƒ“ƒhƒLƒVƒ‹—°Ž_‚ÌÁ‰»ŠÇ“®‘Ԃ̉ð–¾, ‘æ3‰ñ“ú–{t‚Æ–òÜŒ¤‹†‰ïŠwp‘å‰ï2009 (–¼ŒÃ‰®), 2009. 9. 19-20.

 

13)    åM“c’¼Šó, ‚—ÇPŽj, •õŠ_“N–ç, –k“c“¿º, ’Ò–{‰ë”V, ¼ŒûHŽi, ‰¡ŽRÆ—R: –Ô—…“Iˆâ“`Žq”­Œ»‰ðÍ‚ÉŠî‚¢‚½RŽîᇫ”’‹àö‘ÌŠ´Žó«ˆöŽq‚Ì’Tõ, ‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (’·è), 2009. 10. 24-25.

 

14)    Hiroko Honda, Masayuki Tsujimoto, Erika Okamoto, Tetsuya Minegaki, Kohshi Nishiguchi: Effects of continuous ingestion of grapefruit juice on the intestinal absorption of fexofenadine in mice, 24th JSSX Annual Meeting in Kyoto, 2009. 11. 27-29.

 

15)    Daisuke Shima, Masayuki Tsujimoto, Shima Hiraoka, Ayaka Miyoshi, Tetsuya Minegaki, Kohshi Nishiguchi: Mechanism for decreased digoxin concentration by fexofenadine in hemodialysis patients, 24th JSSX Annual Meeting in Kyoto, 2009. 11. 27-29.

 

@@@u‰‰“™

 

1)         ¼ŒûHŽi: ‹ž“s–ò‰È‘åŠwƒI[ƒvƒ“ƒLƒƒƒ“ƒpƒX, ƒ~ƒju‹` (‹ž“s), 2009. 8.

 

2)         ¼ŒûHŽi: _ŒË–ò‰È‘åŠw‘åŠw‰@u‹`, ƒtƒ@[ƒ}ƒVƒ…[ƒeƒBƒJƒ‹ƒPƒA“Á˜_ (_ŒË), 2009. 11.

 

3)         ¼ŒûHŽi, ’Ò–{‰ë”V, •õŠ_“N–ç: ‹ž“s–ò‰È‘åŠwˆê”ÊŒöŠJuÀ, ƒ|ƒXƒ^[ŒfŽ¦ (‹ž“s), 2009. 11.

 

@@@‚»‚Ì‘¼

 

1)           ¼ŒûHŽi: ŽQ‰Á. ‹ž“s–ò‰È‘åŠwE‹ž“s•{•a‰@–òÜŽt‰ï@˜AŒgƒ[ƒNƒVƒ‡ƒbƒv (‹ž“s), 2009. 1.

 

2)           ¼ŒûHŽi: ŽQ‰Á. ‹ž“s•{–òÜŽt‰ïE‹ž“s•{•a‰@–òÜŽt‰ï@ŽÀ–±ŽÀKŽó“ü˜A—‰ï (‹ž“s), 2009. 8.

 

3)           ¼ŒûHŽi: ˆÏˆõ, ‰Û‘èÓ”CŽÒ, ‘Š‡. ‹ž“s–ò‰È‘åŠw@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.

 

4)           ’Ò–{‰ë”V: ‰Û‘èÓ”CŽÒ. ‹ž“s–ò‰È‘åŠw@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.

 

5)           •õŠ_“N–ç: ƒXƒ^ƒbƒtƒ`[ƒt. ‹ž“s–ò‰È‘åŠw@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.

 

6)           ¼ŒûHŽi, ’Ò–{‰ë”V, •õŠ_“N–ç: •]‰¿ŽÒ. “¯ŽuŽÐ—Žq‘åŠw@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.